Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: Immunol Rev. 2023 Jul 16;320(1):58–82. doi: 10.1111/imr.13233

Figure 2. Comparison of Characteristics of TCR T-cell and CAR-T-cell formats.

Figure 2.

(left) TCR therapy targets a large universe of intracellular tumor antigens that are presented on the cell surface as peptide fragments by MHC molecules. The recognition of the antigen occurs via alpha beta TCR/CD3 complex. (right) Most current CAR-T-cell therapies target cell surface and lineage proteins that are shared between tumor and normal cells. The recognition of the target is through the scFv of an mAb directed to the surface target protein, which was linked to the T-cell activation molecules CD28 or 41BB and CD3 zeta chain. All figures were created by using BioRender.